The breast cancer diagnostic pathway includes tissue biopsy, tissue processing, histopathology and, if histopathology reveals invasive cancer, biomarker analysis for three breast cancer biomarkers, including estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 status. Here, ERBB2 is linked to breast carcinoma.